Publication details

Doporučení České společnosti pro trombózu a hemostázu České lékařské společnosti J. E. Purkyně pro bezpečnou léčbu novými perorálními antikoagulancii (NOAC) – dabigatran etexilátem, apixabanem a rivaroxabanem

Title in English Guidelines of Czech Association for Thrombosis and Haemostasis of the Czech Medical Association of J. E. Purkyně for safety treatment with new oral anticoagulants (NOAC) – dabigatran etexilate, apixaban and rivaroxaban
Authors

KVASNIČKA Jan PENKA Miroslav KVASNIČKA Tomáš MICHALCOVÁ Jana KUDRNOVÁ Zuzana MALÍKOVÁ Ivana

Year of publication 2015
Type Article in Periodical
Magazine / Source Vnitřní lékařství
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords apixaban; dabigatran etexilate; NOAC; rivaroxaban
Description There are presently new oral anticoagulants (NOAC) for prevention and the treatment of thromboembolic diseases and they are registered in CZ. It concerns of orally direct inhibitors of thrombin (dabigatran etexilate), inhibitors of factor Xa (apixaban, rivaroxaban), respectively, with advantage of some properties not being seen in „classical” anticoagulants. In the use of new anticoagulants, however, are some problems – such as laboratory monitoring in urgent situations of effective treatment and the absence of specific antidote – resolved. The text below brings indications,dosage of the drugs, their elimination, follow-up of efficacy of the treatment or risk of the bleeding as well as the therapy of bleeding complications.

You are running an old browser version. We recommend updating your browser to its latest version.

More info